TY - JOUR
T1 - A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis
AU - Bissonnette, Robert
AU - Papp, Kim
AU - Maari, Catherine
AU - Yao, Yihong
AU - Robbie, Gabriel
AU - White, Wendy I.
AU - Le, Chenxiong
AU - White, Barbara
PY - 2010/3
Y1 - 2010/3
N2 - Background: Interferon-alfa (IFN-α) has been implicated in the pathogenesis of psoriasis. Objective: To evaluate the safety profile of MEDI-545, a fully human anti-IFN-α monoclonal antibody and to explore its effect on the involvement of type I IFN-α activity in the maintenance of established plaque psoriasis. Methods: We conducted an 18-week, randomized, double-blind, placebo-controlled, dose-escalating study in 36 subjects with chronic plaque psoriasis. Subjects received one intravenous dose of MEDI-545 (0.3-30.0 mg/kg) or placebo. Study outcomes were safety profile, pharmacokinetics, immunogenicity, and clinical effects. Results: There was no difference in adverse events between MEDI-545 and placebo. Two serious adverse events were reported; one drug-related hypotensive infusion reaction occurred in one subject in the 30.0 mg/kg MEDI-545 dose group, causing discontinuation of study drug in that subject and study dismissal of the other subjects in the same cohort; and a myocardial infarction occurred in one subject in the 10 mg/kg MEDI-545 dose group, which was considered to be unrelated to treatment. MEDI-545 was nonimmunogenic, had a half-life of 21 days, showed no significant inhibition of the type I IFN gene signature, and had no clinical activity. Limitations: The study addressed only IFN-α and chronic psoriatic lesions. Conclusion: The safety profile of MEDI-545 supports further clinical development. IFN-α does not appear to be significantly involved in the maintenance of established plaque psoriasis.
AB - Background: Interferon-alfa (IFN-α) has been implicated in the pathogenesis of psoriasis. Objective: To evaluate the safety profile of MEDI-545, a fully human anti-IFN-α monoclonal antibody and to explore its effect on the involvement of type I IFN-α activity in the maintenance of established plaque psoriasis. Methods: We conducted an 18-week, randomized, double-blind, placebo-controlled, dose-escalating study in 36 subjects with chronic plaque psoriasis. Subjects received one intravenous dose of MEDI-545 (0.3-30.0 mg/kg) or placebo. Study outcomes were safety profile, pharmacokinetics, immunogenicity, and clinical effects. Results: There was no difference in adverse events between MEDI-545 and placebo. Two serious adverse events were reported; one drug-related hypotensive infusion reaction occurred in one subject in the 30.0 mg/kg MEDI-545 dose group, causing discontinuation of study drug in that subject and study dismissal of the other subjects in the same cohort; and a myocardial infarction occurred in one subject in the 10 mg/kg MEDI-545 dose group, which was considered to be unrelated to treatment. MEDI-545 was nonimmunogenic, had a half-life of 21 days, showed no significant inhibition of the type I IFN gene signature, and had no clinical activity. Limitations: The study addressed only IFN-α and chronic psoriatic lesions. Conclusion: The safety profile of MEDI-545 supports further clinical development. IFN-α does not appear to be significantly involved in the maintenance of established plaque psoriasis.
UR - http://www.scopus.com/inward/record.url?scp=76249118401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76249118401&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2009.05.042
DO - 10.1016/j.jaad.2009.05.042
M3 - Article
C2 - 20159310
AN - SCOPUS:76249118401
SN - 0190-9622
VL - 62
SP - 427
EP - 436
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 3
ER -